tiprankstipranks
Advertisement
Advertisement
OncoCyte Earnings Call: GraftAssureDx Drives Pivot
PremiumCompany AnnouncementsOncoCyte Earnings Call: GraftAssureDx Drives Pivot
2M ago
Buy Rating on IMDX Driven by Strong GraftAssure Traction, Upcoming FDA Catalyst, and Solid Balance Sheet
Premium
Ratings
Buy Rating on IMDX Driven by Strong GraftAssure Traction, Upcoming FDA Catalyst, and Solid Balance Sheet
2M ago
Insight Molecular Diagnostics submits GraftAssureDx for FDA review
Premium
The Fly
Insight Molecular Diagnostics submits GraftAssureDx for FDA review
2M ago
Insight Molecular Diagnostics: GraftAssureIQ Validation and Hospital Adoption Set Up 2026 as a Growth Inflection Year
PremiumRatingsInsight Molecular Diagnostics: GraftAssureIQ Validation and Hospital Adoption Set Up 2026 as a Growth Inflection Year
3M ago
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement
Premium
Company Announcements
Insight Molecular Diagnostics Signs Quest Specimen Collection Agreement
3M ago
Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street
Premium
The Fly
Insight Molecular Diagnostics price target raised to $12 from $8 at Lake Street
3M ago
Insight Molecular Diagnostics appoints Nick Ioannou as VP, medical affairs
PremiumThe FlyInsight Molecular Diagnostics appoints Nick Ioannou as VP, medical affairs
5M ago
Regulatory Momentum and Expanding Clinical Footprint Position Insight Molecular Diagnostics for a Pivotal 2026 Ramp
Premium
Ratings
Regulatory Momentum and Expanding Clinical Footprint Position Insight Molecular Diagnostics for a Pivotal 2026 Ramp
5M ago
iMDx prepares for U.S. commercial launch of GraftAssureDx
Premium
The Fly
iMDx prepares for U.S. commercial launch of GraftAssureDx
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100